X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
https://www.globenewswire.com//news-release/2023/10/17/2761904/35186/en/Kura-Oncology-Announces-Positive-Results-from-Registration-Directed-Study-of-Tipifarnib-in-Patients-with-HRAS-Mutant-HNSCC.html
https://endpts.com/kura-oncology-drops-multiple-clinical-programs-for-jj-discovered-tipifarnib/
https://www.globenewswire.com/news-release/2022/10/26/2541689/35186/en/Kura-Oncology-Reports-Preliminary-Proof-of-Mechanism-in-Phase-1-2-Clinical-Trial-of-Tipifarnib-Plus-Alpelisib-in-Head-and-Neck-Squamous-Cell-Carcinoma.html
https://www.globenewswire.com/news-release/2021/12/16/2353801/35186/en/Kura-Oncology-Doses-First-Patient-in-Phase-1-2-Clinical-Trial-of-Tipifarnib-in-Combination-with-Alpelisib-in-Head-and-Neck-Squamous-Cell-Carcinoma.html
https://www.globenewswire.com/news-release/2021/12/13/2350963/35186/en/Kura-Oncology-Reports-Final-Results-from-Phase-2-Study-of-Tipifarnib-in-T-Cell-Lymphoma.html
https://www.globenewswire.com/news-release/2021/03/22/2197210/0/en/Kura-Oncology-Announces-Publication-of-Tipifarnib-Phase-2-Data-in-Journal-of-Clinical-Oncology.html
https://www.globenewswire.com/news-release/2021/03/22/2197210/0/en/Kura-Oncology-Announces-Publication-of-Tipifarnib-Phase-2-Data-in-Journal-of-Clinical-Oncology.html#:~:text=Oncology%20Nasdaq%3AKURA-,Kura%20Oncology%20Announces%20Publication%20of%20Tipifarnib%20Phase,in%20Journal%20of%20Clinical%20Oncology&text=Median%20progression%2Dfree%20survival%20(PFS,therapy%20(p%3D0.0012).
https://ir.kuraoncology.com/news-releases/news-release-details/kura-oncology-receives-fda-breakthrough-therapy-designation
https://www.globenewswire.com/news-release/2020/10/26/2114168/0/en/Kura-Oncology-Reports-Preclinical-Results-Showing-Antitumor-Activity-of-Tipifarnib-in-Combination-with-PI3K%CE%B1-Inhibitor-in-Head-and-Neck-Squamous-Cell-Carcinoma.html
https://endpts.com/kura-flashes-positive-hras-data-on-once-failed-jj-drug/
https://endpts.com/effector-co-founder-siegfried-reich-jumps-to-turning-point-antonio-gualberto-starts-post-kura-career-at-eisai-subsidiary-h3/
https://www.dddmag.com/news/2017/07/kura-oncology-establishes-collaboration-foundation-medicine-support-tipifarnib-development
Market Place
Share 
